Hormone replacement therapy in women with a history of breast cancer

References

• Broeders MJM, Verbeek ALM. Breast cancer epidemiology and risk factors. Q J Nud Med 1997;41:179–88
   PubMedGoogle Scholar
• LOpez-Otin C, Diamondis EP. Breast and prostate cancer: An analysis of common epidemiological, genetic, and biochemical features. Endocr Rev 1998;19:365–96
   Google Scholar
• Finnish Cancer Registry — Institute for Statistical and Epidemiological Cancer Research. Cancer Incidence in Finland 1996 and 1997. Helsinki: Can-cer Society of Finland, Publication No. 61, 2000
   Google Scholar
• Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replace-ment therapy: collaborative reanalysis of data from 51 epidemiological studies on 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet 1997;350:1047–59
   PubMed Web of Science ®Google Scholar
• SEER Cancer Statistics Review 1973-98. Washing-ton, DC: National Cancer Institute, 2001
   Google Scholar
• Klemi PJ, Jo ensuu H, Toikkanen J, et al. Aggressiveness of breast cancer found with and without screening. BMJ 1992;304:467–9
   PubMedGoogle Scholar
• Peto R, Boreham J, Clarke M, et al. UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years. Lancet 2000;355:1822
   Google Scholar
• Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 1992;339:1-5, 71–85
   Google Scholar
• Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet 1998;351:1451–67
   Google Scholar
• Gadducci A, Genazzani AR. Endocrine therapy for gynecological cancer. Gynecol Endocrinol 1999;13: 441–56
   PubMed Web of Science ®Google Scholar
• Joensuu H, Toikkanen S. Identification of sub-groups with favorable prognosis in breast cancer. Acta Oncol 1992;31:293–301
   PubMed Web of Science ®Google Scholar
• Kelsey JL, Gammon MD, John EM. Reproductive factors and breast cancer. Epidemiol Rev 1993; 15:36–47
   Google Scholar
• Gregoraszczuk EL, Milewicz T, Kolodziejczyk J, et al. Progesterone-induced secretion of growth hormone, insulin-like growth factor I and prolactin by human breast cancer explants. Gynecol Endocrinol 2001;15:251–8
   PubMed Web of Science ®Google Scholar
• Persson I, Weiderpass F, Bergkvist I, et al. Risks of breast and endometrial cancer after estrogen and estrogen-pro gestin replacement. Cancer Causes Control 1999;10:253–60
   PubMed Web of Science ®Google Scholar
• Ross RK, Paganini-Hill A, Wan PC, et al. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 2000;92:328–32
   PubMed Web of Science ®Google Scholar
• Schairer C, Lubin J, Troisi R, et al. Menopausal estrogen and estrogen-pro gestin replacement therapy and breast cancer risk. J Am Med Assoc 2000;283:485–91
   PubMed Web of Science ®Google Scholar
• Dixon JM. Hormone replacement therapy and the breast. BMJ 2001;323:1381–2
   PubMedGoogle Scholar
• Marchant DJ. Supplemental estrogen replacement. Cancer 1994;74:512–17
   PubMed Web of Science ®Google Scholar
• Colditz GA. Estrogen replacement therapy for breast cancer patients. Oncology 1997;11:1491–7
   PubMedGoogle Scholar
• Consensus Statement. Treatment of estrogen deficiency symptoms in women surviving breast cancer. J Clin Endocrinol Metab 1998;83:1993–2000
   PubMed Web of Science ®Google Scholar
• Bush TL, Whiteman M, Flaws A. Hormone replacement therapy and breast cancer: A qualita-tive review. Obstet Gynecol 2001;98:498–508
   Google Scholar
• Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992; 117:1016–37
   PubMed Web of Science ®Google Scholar
• Maxim P, Ettinger B, Spitalny GM. Fracture protection provided by long-term estrogen treat-ment. Osteoporosis Int 1995;5:23–9
   Google Scholar
• Weiss SR, Ellman H, Dolker M. A randomized controlled trial of four doses of transdermal estradiol for preventing postmenopausal bone loss. Obstet Gynecol 1999;94:330–6
   Google Scholar
• Burkman RT, Collins JA, Greene RA. Current perspectives on benefits and risks of hormone replacement therapy. Am J Obstet Gynecol 2001; 185:513–23
   Google Scholar
• Mijatovic V, van der Mooren MJ, Stehouwer CDA, et al. Postmenopausalhormone replacement, risk estimators for coronary artery disease and cardiovascular protection. Gynecol Endocrinol 1999;13:130–44
   PubMed Web of Science ®Google Scholar
• Windler E. Modification of serum lipids and cardiovascular risk by estrogenic active com-pounds. Gynecol Endocrinol 1999;13(Suppl 6):21–8
   PubMedGoogle Scholar
• Ylikorkala O. Balancing between observational studies and randomized trials in prevention of coronary heart disease by estrogen replacement: HERS study was no revolution. Acta Obstet Gynecol Scand 2000;79:1029–36
   PubMed Web of Science ®Google Scholar
• Grodstein F, Manson JE, Stampfer MJ. Post-menopausal hormone use and secondary prevention of coronary events in the Nurse's Health Study: a prospective, observational study. Ann Intern Med 2001;135:1–8
   Google Scholar
• Mendelsohn ME, Karas RH. The time has come to stop letting the HERS tale wag the dogma. Circulation 2001;104:2256–9
   PubMed Web of Science ®Google Scholar
• Shlipak MG, Angeja BG, Go AS, et al. Hormone therapy and in-hospital survival after myocardial infarction in postmenopausal women. Circulation 2001;104:2300–4
   PubMed Web of Science ®Google Scholar
• Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. J Am Med Assoc 1998;280:605–13
   PubMed Web of Science ®Google Scholar
• Herrington DM, Reboussin DM, Broshnihan KB, et al. Effects of estrogen replacement on the pro-gression ofcoronary-artery atherosclerosis. N Eng1J Med 2000;343:522–9
   PubMed Web of Science ®Google Scholar
• Marsden J, Whitehead M, A'Hern R, et al. Are randomized trials of hormone replacement therapy in symptomatic women with breast cancer feasible? Fertil Steril 2000;73:292–9
   Google Scholar
• Wile AG, Opfell RW, Margileth DA. Hormone replacement therapy in previously treated breast cancer patients. Am J Surg 1993;165:372–5
   Google Scholar
• DiSaia PJ, Odicino F, Grosen EA, et al. Hormone replacement therapy in breast cancer. Lancet 1993; 342:1232
   PubMed Web of Science ®Google Scholar
• Powles TJ, Hickish T, Casey S, et al. Hormone replacement after breast cancer. Lancet 1993;342: 60–1
   PubMed Web of Science ®Google Scholar
• Eden JA, Bush T, Nand S, et al. A case-control study of combined continuous estrogen-progestin replacement therapy among women with a personal history of breast cancer. Menopause 1995;2:67–72
   Web of Science ®Google Scholar
• Vassilopoulou-Sellin R, Theriault R, Klein MJ. Oestrogen replacement therapy in women with prior diagnosis and treatment for breast cancer. Gynecol Oncol 1997;65:89–93
   Google Scholar
• Natraj an PK, Soumakis K, Gambrell RD. Estrogen replacement therapy in women with previous breast cancer. Am J Obstet Gynecol 1999;181: 288–95
   Google Scholar
• Ursic-Vrscaj M, Bebar S. A case control study of hormone replacement therapy after primary surgical breast cancer treatment. Eur J Surg Oncol 1999;25:146–51
   Google Scholar
• O'Meara ES, Rossing MA, Daling JR, et al. Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality. J Natl Cancer Inst 2001;93:754
   PubMed Web of Science ®Google Scholar
• Marttunen MB, Hietanen P, Pyrhönen S, et al. A prospective study on women with a history of breast cancer and with or without estrogen replace-ment therapy. Maturitas 2001;39:217–25
   Google Scholar
• Schindler AE. Role of progestins in the premenopausal climacteric. Gynecol Endocrinol 1999;13\(Supp16):35–40
   Google Scholar
• Adami H-0, Bergstrom R, Weiderpass, et al. Risk for endometrial cancer following breast cancer: a prospective study in Sweden. Cancer Causes Control 1997;8: 821–7
   Google Scholar
• Gambrell RD Jr. Strategies to reduce the incidence of endometrial cancer in postmenopausal women. Am J Obstet Gynecol 1997;177:1196–207
   PubMed Web of Science ®Google Scholar
• Benedek-Jaszmann IT Long-term placebo-controlled efficacy and safety study of Org 0D14 in climacteric women. Maturitas 1987;9 (Suppl 1): 25–33
   PubMedGoogle Scholar
• Punnonen R, Liukko P, Cortes-Prieto J, et al. Multicentre study of effects of ORG 0D14 on endometrium, vaginal cytology and cervical mucus in post-menopausaland oophorectomized women. Maturitas 1984;5: 281–6
   Google Scholar
• Genazzani AR, Benedek-Jaszmann U, Hart DM, et al. Org 0D14 and the endometrium. Maturitas 1991;13:243–51
   PubMed Web of Science ®Google Scholar
• Pavlov PW, Ginsburg J, Kicovic PM, et al. Double-blind, placebo-controlled study of the effects of tibolone on bone mineral density in postmenopausal osteoporotic women with and without previous fractures. Gynecol Endocrinol 1999;13:230–7
   PubMed Web of Science ®Google Scholar
• Lundstrom E, Christow A, Kersemaekers W, et al. Effects of tibolone and a continuous combined HRT regimen on mammographic breast density. Am J Obstet Gynecol 2002;186:717–22
   PubMed Web of Science ®Google Scholar
• Kavanagh AM, Mitchell H, Giles GG. Hormone replacement therapy and accuracy of graphic screening. screening. Lancet 2000;355:270–4
   Google Scholar
• Saarto T, Blomqvist C, Ehnholm C, et al. Anti-atherogenic effects of adjuvant antiestrogens: a randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with node-positive breast cancer. J Clin Oncol 1996;14:429–33
   PubMed Web of Science ®Google Scholar
• Marttunen MB, Hietanen P, Tiitinen A, et al. Comparison of effects of tamoxifen and toremifene on bone biochemistry and bone mineral density in postmenopausal breast cancer patients. J Clin Endocrinol Metab 1998;83:1158–62
   PubMed Web of Science ®Google Scholar
• Marttunen MB, Hietanen P, Tiitinen A, et al. Effects of tamoxifen and toremifene on urinary excretion of pyridinoline and deoxypyridinoline and bone density in postmenopausal patients with breast cancer. Calqf Tissue Int 1999;65:365–8
   PubMed Web of Science ®Google Scholar
• Marttunen MB, Pyrhönen S, Tiitinen A, et al. Effect of antiestrogen regimen on prostacyclin and thromboxane A2 in postmenopausal patients with breast cancer: evidence of significance of hyper-tension, smoking or previous use of estrogen therapy. Prostaglandins 1996;52:317–26
   PubMed Web of Science ®Google Scholar
• Marttunen MB, Hietanen P, Tiitinen A, et al. Antiestrogens reduce plasma levels of endothelin-1 without affecting nitrate levels in breast cancer patients. Gynecol Endocrinol 2000;14:55–9
   PubMed Web of Science ®Google Scholar
• Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausalwomen with osteoporosis treated with raloxifene. JAm Med Assoc 1999;282:637–45
   PubMed Web of Science ®Google Scholar
• Genazzani AR, Bernardi F, Stomati M, et al. Raloxifene analog LY 117018 effects on central and peripheral I3-endorphin. Gynecol Endocrinol 1999;4:111
   Google Scholar
• DeGregorio MW, Wurz GT, Taras TL, et al. Pharmacokinetics of (deaminohydroxy) toremifene in humans: a new, selective estrogen-receptor modulator. Eur J Clin Pharmacol 2000;56: 469–75
   PubMed Web of Science ®Google Scholar
• Pas qualini JR, Ebert C, Chetrite GS. The SEEM: selective estrogen enzyme modulators in breast cancer. Gynecol Endocrinol 1999;13(Suppl 6):1–8
   Google Scholar
• Ylikorkala O. Clonidine in the treatment of menopausal symptoms. Ann Chir Gynaecol Fenn 1975;64:242–5
   PubMedGoogle Scholar
• Goldberg RI\4, Loprinzi CL, O'Fallon JR, et al. Transdermal clonidine for ameliorating tamoxifen-induced hot flashes. J Clin Oncol 1994;12:155–8
   Google Scholar
• Barton D, Loprinzi CL, Quella SK, et al. Prospective evaluation of vitamin E for hot flushes in breast cancer survivors. J Clin Oncol 1998; 16:495–500
   PubMed Web of Science ®Google Scholar
• Loprinzi CL, Pisansky T, Fonseca R, et al. Pilot evaluation of venlafaxine hydrochloride for the therapy of hot flashes in cancer survivors. J Clin Oncol 1998;16:2377–81
   PubMed Web of Science ®Google Scholar
• Loprinzi CL, Kugler JW, Sloan JA, et al. Venlafaxine in management of hot flushes in survivors of breast cancer: randomized controlled trial. Lancet 2000;556:2059–63
   Google Scholar
• Davis SR. Phytoestrogen therapy for menopausal symptoms: there is no good evidence that it is better than placebo. BMJ 2001;323:354–5
   PubMedGoogle Scholar
• Loprinzi CL, Michalak JC, Quella SK, et al. Megestrol acetate for the prevention of hot flushes. N Engl J Med 1994;331:347–52
   PubMed Web of Science ®Google Scholar
• Quella SK, Loprinzi CL, Sloan JA, et al. Long-term use of megestrol acetate for treatment of hot flushes in cancer survivors. Cancer 1998;82:1784–8
   PubMed Web of Science ®Google Scholar
• Suhonen S, Holmstrom T, Lähteennijki P. Three-year following study of the use of a levonorgestrel-releasing intrauterine system in hormone replacement therapy. Acta Obstet Gynecol Scand 1997;76:145–50
   Google Scholar
• Suvanto-Luukkonen E, Malinen H, Sundström H, et al. Endometrial morphology during hormone replacement therapy with estradiol gel combined to levo no rgestrel-releasing intrauterine device or natural progesterone. Acta Obstet Gynecol Scand 1998;77:758–63
   Google Scholar
• Varila E, Wahlström T, Rauramo I. A 5-year follow-up study on the use of a levonorgestrel intrauterine system in women receiving hormone replacement therapy. Fertil Steril 2001;76:969–73
   PubMed Web of Science ®Google Scholar
• Wotczynski S, Surazynski A, Swiatecka J, et al. Estrogenic and antiestrogenic effect of raloxifene on collagen metabolism in breast cancer MCF-7 cells. Gynecol Endocrinol 2001;15:225–33
   PubMed Web of Science ®Google Scholar